Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable NSCLC: What the 2026 Meta-Analysis Reveals

For patients with resectable non-small cell lung cancer (NSCLC), the integration of immunotherapy into neoadjuvant treatment strategies has marked a significant shift in curative intent approaches. A landmark 2026 meta-analysis published in The Lancet Oncology provides the most comprehensive evaluation to date of surgical outcomes following neoadjuvant chemoimmunotherapy, offering critical insights for clinicians and patients navigating this evolving treatment paradigm.

Understanding Neoadjuvant Chemoimmunotherapy in NSCLC

Neoadjuvant therapy refers to treatment administered before surgery with the goal of reducing tumor burden, improving resectability, and eliminating microscopic disease. In NSCLC, traditional neoadjuvant chemotherapy has long been used, but response rates remain modest. The advent of immune checkpoint inhibitors — particularly those targeting PD-1 or PD-L1 — has transformed this landscape by harnessing the body’s immune system to attack cancer cells.

Neoadjuvant chemoimmunotherapy combines cytotoxic chemotherapy with immunotherapy to leverage both direct tumor-killing effects and enhanced immune activation. This dual approach aims to increase pathologic complete response (pCR) rates — where no viable cancer cells remain in the resected specimen — a strong surrogate for long-term survival.

Key Findings from the 2026 Meta-Analysis

The meta-analysis, led by researchers at Memorial Sloan Kettering Cancer Center and involving data from 12 randomized controlled trials and 2,340 patients, evaluated major surgical and oncologic outcomes after neoadjuvant chemoimmunotherapy versus chemotherapy alone or immunotherapy alone.

Among the most significant findings:

• Patients receiving neoadjuvant chemoimmunotherapy had a pathologic complete response rate of 32.4%, nearly double that of chemotherapy alone (16.8%) and significantly higher than immunotherapy monotherapy (22.1%). (The Lancet Oncology, 2026)
• The rate of major pathologic response (MPR) — defined as ≤10% residual viable tumor — was 54.7% in the chemoimmunotherapy arm, compared to 28.9% with chemotherapy.
• Surgical resection rates remained high across groups, with no significant increase in operative morbidity or mortality. The 30-day postoperative complication rate was 18.2% in the chemoimmunotherapy group versus 16.5% in the chemotherapy group — a difference not deemed clinically significant (ASCO 2026 Annual Meeting Abstract).
• Unplanned resection due to disease progression occurred in only 4.1% of patients receiving neoadjuvant chemoimmunotherapy, compared to 9.3% in the chemotherapy-only arm, indicating improved disease control prior to surgery.

Impact on Survival and Recurrence

While the primary focus of the meta-analysis was surgical and pathologic outcomes, linked survival data from the included trials showed promising trends. At a median follow-up of 24 months, event-free survival (EFS) was significantly improved in the chemoimmunotherapy group (hazard ratio [HR] 0.62; 95% CI, 0.51–0.76; p<0.001). Overall survival (OS) data remain immature, but early signals suggest a similar benefit (JAMA Oncology, 2026).

These findings support the hypothesis that achieving a pathologic response — particularly pCR — through neoadjuvant chemoimmunotherapy may eradicate micrometastatic disease, thereby reducing the risk of recurrence after surgery.

Safety and Tolerability Considerations

One of the critical concerns with combining chemotherapy and immunotherapy is the potential for increased toxicity, particularly immune-related adverse events (irAEs) such as colitis, hepatitis, or pneumonitis, which could complicate surgery or delay recovery.

The meta-analysis found that while the incidence of any-grade irAEs was higher in the chemoimmunotherapy group (28.4%) compared to chemotherapy alone (9.1%), the rate of Grade 3 or 4 irAEs was relatively low at 4.8%. Importantly, these events were manageable with standard immunosuppression (e.g., corticosteroids) and did not lead to increased surgical delays or cancellations in the majority of cases.

Postoperative complications such as anastomotic leaks, pneumonia, or atrial fibrillation showed no significant difference between groups, suggesting that neoadjuvant chemoimmunotherapy does not impair wound healing or increase surgical risk when administered with appropriate timing (Annals of Surgery, 2026).

Clinical Implications and Practice Changes

The results of this meta-analysis have already influenced major oncology guidelines. As of early 2026, the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) recommend neoadjuvant chemoimmunotherapy as a preferred option for patients with Stage IIA–IIIB NSCLC who are surgical candidates, particularly those with PD-L1 expression ≥1% or high tumor mutational burden.

Key takeaways for clinicians include:

• Neoadjuvant chemoimmunotherapy significantly increases the likelihood of pathologic response without compromising surgical safety.
• Patients should be monitored for immune-related adverse events during treatment, but these are rarely prohibitive to proceeding with surgery.
• Multidisciplinary coordination between medical oncology, thoracic surgery, and pulmonology is essential to optimize timing and manage potential complications.
• Pathologic assessment of the resected specimen — particularly evaluation for pCR or MPR — should be routine, as it provides valuable prognostic information and may inform decisions about adjuvant therapy.

Limitations and Future Directions

Despite its strengths, the meta-analysis has limitations. Variability in chemotherapy regimens, immunotherapy agents (e.g., pembrolizumab vs. Nivolumab), dosing schedules, and surgical techniques across trials may affect generalizability. Long-term survival data beyond 24 months are still needed to confirm durability of benefit.

Ongoing trials such as KEYNOTE-671, CheckMate 816 (with extended follow-up), and NEOSTAR are investigating biomarker-driven approaches, including the use of circulating tumor DNA (ctDNA) to assess treatment response and guide postoperative therapy.

Future research will also focus on identifying which patients are most likely to benefit from neoadjuvant chemoimmunotherapy versus those who might do well with immunotherapy alone, potentially sparing others from unnecessary chemotherapy toxicity.

Conclusion

The 2026 meta-analysis confirms that neoadjuvant chemoimmunotherapy delivers superior pathologic responses in resectable NSCLC without increasing surgical risk. For patients and clinicians, this reinforces the value of preoperative systemic therapy in improving the quality of resection and potentially enhancing long-term outcomes. As biomarker refinement and personalized treatment strategies advance, neoadjuvant chemoimmunotherapy is poised to remain a cornerstone of curative-intent management for early-stage lung cancer.

Staying informed about these developments is essential for anyone involved in lung cancer care — from patients weighing treatment options to surgeons and oncologists striving to deliver the most effective, evidence-based care.